IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain Post author:Sam Post published:February 2, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like CytoSorbents Launches VetResQ For U.S. Veterinary Market January 19, 2017 CTI BioPharma Reports First Quarter 2017 Financial Results May 3, 2017 Arena To Provide Corporate Update And Release Fourth Quarter And Full-Year 2016 Financial Results On Tuesday, March 14, 2017 March 6, 2017
Arena To Provide Corporate Update And Release Fourth Quarter And Full-Year 2016 Financial Results On Tuesday, March 14, 2017 March 6, 2017